Glucagon
A pancreatic hormone that opposes insulin — raises blood glucose, promotes lipolysis and ketogenesis.
Glucagon is a 29-amino-acid peptide hormone secreted by pancreatic α-cells when blood glucose drops. It opposes insulin: stimulating hepatic glycogenolysis and gluconeogenesis to raise blood glucose, and promoting adipose lipolysis and hepatic ketogenesis during fasting. Glucagon receptor agonism is investigated in research literature for hepatic-fat reduction (the rationale behind retatrutide's third receptor arm). Therapeutic glucagon agonism is balanced against the diabetic-glucose-spike risk; co-agonism with GLP-1 / GIP (incretins) provides counter-regulatory cover.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue
- ResearchRetatrutide 30 mg kit
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.
- ResearchRetatrutide 10 mg kit
Retatrutide 10 mg lyophilised vial kit — entry-point research presentation. Includes bac water, syringes, swabs.
- GlossaryGLP-1
Glucagon-like peptide-1, an incretin hormone that regulates glucose and appetite.
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.